[1] Seto WK,Yuen MF.Nonalcoholic fatty liver disease in Asia:emerging perspectives.J Gastroenterol,2017,52:164-174.
[2] Eslam M,Newsome PN,Anstee QM,et al.A new definition for metabolic associated fatty liver disease:an international expert consensus statement [published online ahead of print, 2020 Apr 8].J Hepatol,2020,S0168-8278:30201-30204.
[3] Angulo P,Kleiner DE,Dam-Larsen S,et al.Liver fibrosis,but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology,2015,149:389-397.
[4] Singh S, Allen AM, Wang Z,et al.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol,2015,13:643–e40.
[5] Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia.J Hepatol,2017,67:862-873.
[6] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology,2016,64:73-84.
[7] Li J,Zou B,Yeo YH,et al.Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:a systematic review and meta-analysis.Lancet Gastroenterol Hepatol,2019,4:389-398.
[8] Zhou F,Zhou J,Wang W,et al.Unexpected rapid increase in the Burden of NAFLD in China From 2008 to 2018:A Systematic Review and Meta-Analysis.Hepatology,2019,70:1119-1133.
[9] Sanyal AJ.Past,present and future perspectives in nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol,2019,16:377-386.
[10] Leoni S,Tovoli F,Napoli L,et al.Current guidelines for the management of non-alcoholic fatty liver disease:a systematic review with comparative analysis.World J Gastroenterol,2018,24:3361-3373.
[11] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21:177-186.
[12] European Association for the Study of the Liver (EASL),European Association for the Study of Diabetes (EASD),European Association for the Study of Obesity (EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol,2016,64:1388-1402.
[13] National Institute for Health and Care Excellence (UK).NonAlcoholic Fatty Liver Disease:Assessment and Management.NICE Guideline,2016,Available from: URL: http//www.niceorg.uk/guidance/ng49
[14] Wong VW,Chan WK,Chitturi S,et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 1:Definition,risk factors and assessment.J Gastroenterol Hepatol,2018,33:70-85.
[15] Chitturi S,Wong VW,Chan WK,et al.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 2:Management and special groups.J Gastroenterol Hepatol,2018,33:86-98.
[16] Italian Association for the Study of the Liver (AISF).AISF position paper on nonalcoholic fatty liver disease (NAFLD):Updates and future directions.Dig Liver Dis,2017,49:471-483.
[17] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice Guidance from the American Association for the Study of Liver Diseases.Hepatology,2018,67:328-357.
[18] Sumida Y,Yoneda M.Current and future pharmacological therapies for NAFLD/NASH.J Gastroenterol,2018,53:362-376.
[19] Estes C,Anstee QM,Arias-Loste MT,et al.Modeling NAFLD disease burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the period 2016-2030.J Hepatol,2018,69:896-904.
[20] Younossi Z,Tacke F,Arrese M,et al.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Hepatology,2019,69:2672-2682.
[21] Kim D,Kim WR.Nonobese fatty liver disease.Clin Gastroenterol Hepatol,2017,15:474-485.
[22] Leung JC,Loong TC,Wei JL,et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.Hepatology,2017,65:54-64.
[23] Wong VW,Wong GL,Chan RS,et al.Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.J Hepatol,2018,69:1349-1356.
[24] 曾静,孙婉璐,陈光榆,等.FibroTouch与FibroScan肝脏硬度和脂肪定量检测效能的比较.中华肝脏病杂志,2016,24:652-658.
[25] Li Q,Dhyani M,Grajo JR,et al.Current status of imaging in nonalcoholic fatty liver disease.World J Hepatol,2018,10:530-542.
[26] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases.Hepatology,2018,67:328-357.
[27] Konerman MA,Jones JC,Harrison SA.Pharmacotherapy for NASH:current and emerging.J Hepatol,2018,68:362-375.
[28] 中华医学会内分泌学分会.非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版).中华内分泌代谢杂志,2018,34:549-554.
[29] Vilar-Gomez E,Chalasani N.Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers.J Hepatol,2018,68:305-315.
[30] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis.J Hepatol,2015,63:237-264.
[31] Castera L,Friedrich-Rust M,Loomba R.Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.Gastroenterology,2019,156:1264-1281. |
